Southern RNA is an innovative biotechnology company that specializes in RNA-based products and technologies. This article explores the science behind Southern RNA, delves into its diverse range of products, and discusses their transformative applications in medicine and biotechnology.
RNA Technologies: RNA, or ribonucleic acid, is a critical molecule in biology, acting as the intermediary between DNA and proteins. Recent advances in RNA technologies have opened new possibilities in therapeutics, diagnostics, and genetic engineering.
Southern RNA is an Australian contract development and manufacturing organisation (CDMO) specialising in producing nucleic acid products that support the clinical development of therapeutic products. We support our clients by providing scalable manufacturing capacity and help them accelerate innovation in bringing their products from benchtop to bedside or field.
Our goal at Southern RNA is to establish end-to-end manufacturing capabilities in Australia for nucleic acid products such as mRNA and DNA. We strive towards this goal daily by developing and deploying our state-of-the-art bioprocessing technologies, using proprietary manufacturing and analytical approaches.
Product Portfolio:
- Our GMP-Start™ plasmid DNA can be used in mRNA or viral vector manufacturing as a starting material (e.g., AAV, adenovirus, or lentivirus) for in vitro or in vivo applications.
- Our GMP-Start™ mRNA can be used as mRNA drug substance material (e.g., LNP-mRNA vaccine, CAR-T cell manufacturing) for in vitro or in vivo applications.
- Our GMP mRNA can be used as mRNA drug substance for a GMP mRNA vaccine.
Introducing CO CAP™ A
Southern RNA's Co Cap™ A is a novel co-transcriptional capping reagent designed for mRNA synthesis. Co Cap™ is a synthetic trinucleotide cap analogue m7Gppp(2'OMeA)pG that produces 5'Cap 1 m RNA when used as part of in vitro transcription (IVT) reaction enhancing mRNA stability and translational efficiency. We supply in solution at 100±5 mM in various volumes (20µL, 100µL, 1ml & 5ml).
- License-free and seamlessly integrated into the IVT process
- Requires a modified T7 RNA polymerase promoter.
- Full Quality Control testing complete with CoA, tested against qualified QC assay
- Research or GMP-Grade available
- Sodium salt form and other Cap also available
- 24 months stability data
Challenges and Future Directions: Despite the promise of RNA technologies, challenges such as delivery methods, stability, and off-target effects remain. Ongoing research aims to overcome these obstacles and expand the applications of RNA-based products.
Author : Dr Sachin Salunkhe , Senior Manager, Business Development.
Email : [email protected]
